News & Updates

In the treatment of bacterial vaginosis, dequalinium chloride is noninferior to metronidazole, with similarly high cure rates but better tolerability and fewer adverse events, according to a phase IV study.

Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.

Neoadjuvant pembrolizumab plus chemotherapy improves event-free survival (EFS) in high-risk, early-stage triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB), suggests a study.